The “Tech Royalty” Retirement Plan Can Help You Live Like Royalty
For the first time ever, a new type of tech investment allows you to collect ongoing income. One former Wall Street insider calls them, “Tech Royalties.”

And new “Tech Royalty” savings accounts allow you to collect as much as 8%... 12%... and even 17% or more.
Find out why “Tech Royalties” may be the best asse
Jin-Long Chen, insider at NGM Biopharmaceuticals

Jin-Long Chen Insider Information

Dr. Chen is NGM’s Founder and has served as a member of our board of directors and as Chief Scientific Officer since January 2008. He was also NGM’s President until November 2014. Previously, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Disorders, with responsibility for leading the company’s global research efforts in small molecule and biologic drug discovery for the treatment of human diseases affecting metabolism, bone, mineral balance and muscle. Prior to joining Amgen, he served as Vice President of Biology at Tularik where he guided drug discovery research in oncology, inflammation and metabolic disease. Dr. Chen’s pioneering work on a broad array of targets at both Amgen and Tularik not only opened up opportunities to study new aspects of biology and physiology across disease areas, but also led to contributions of multiple drug candidates to the development pipelines of these organizations, including RepathaTM (evolocumab), a novel anti-PCSK9 antibody that lowers low-density lipoprotein cholesterol.

Dr. Chen received a B.S. in Nutrition and Food Science from Fu-Jen Catholic University, and a M.S. in biochemistry from National Taiwan University. He completed his graduate training at the University of California, Berkeley in 1994, receiving a Ph.D. for his research on the mechanisms of transcription carried out in the laboratory of Prof. Robert Tjian.

What is Jin-Long Chen's net worth?

The estimated net worth of Jin-Long Chen is at least $21.04 million as of April 12th, 2021. Dr. Chen owns 945,005 shares of NGM Biopharmaceuticals stock worth more than $21,035,811 as of September 26th. This net worth estimate does not reflect any other investments that Dr. Chen may own. Learn More.

What is Jin-Long Chen's salary?

As the Insider of NGM Biopharmaceuticals, Inc., Dr. Chen earned a total compensation package of $2,368,073.00 in 2020. Dr. Chen earned a salary of $515,000.00, a bonus of $175,000.00, options awards of $1,677,323.00, and other compensation of $750.00.

How do I contact Jin-Long Chen?

The corporate mailing address for Dr. Chen and other NGM Biopharmaceuticals executives is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. NGM Biopharmaceuticals can also be reached via phone at (650) 243-5555 and via email at [email protected]

Has Jin-Long Chen been buying or selling shares of NGM Biopharmaceuticals?

In the last ninety days, Jin-Long Chen has sold $757,350.00 in shares of NGM Biopharmaceuticals stock. Most recently, Jin-Long Chen sold 15,000 shares of the business's stock in a transaction on Monday, September 13th. The shares were sold at an average price of $26.03, for a transaction totalling $390,450.00.

Are insiders buying or selling shares of NGM Biopharmaceuticals?

During the last twelve months, insiders at the sold shares 7 times. They sold a total of 155,000 shares worth mmore than $3,897,850.00. The most recent insider tranaction occured on September, 13th when Jin-Long Chen Insider bought 15,000 shares worth more than $390,450.00. Insiders at NGM Biopharmaceuticals own 45.9 % of the company.

Information on this page was last updated on 9/13/2021.

Jin-Long Chen Insider Trading History at NGM Biopharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2021Sell15,000$26.03$390,450.00View SEC Filing Icon  
8/9/2021Sell15,000$24.46$366,900.00View SEC Filing Icon  
4/12/2021Sell25,000$24.65$616,250.00945,005View SEC Filing Icon  
3/1/2021Sell25,000$26.66$666,500.00970,005View SEC Filing Icon  
1/4/2021Sell25,000$29.28$732,000.00870,375View SEC Filing Icon  
12/14/2020Sell25,000$28.01$700,250.00908,879View SEC Filing Icon  
10/12/2020Sell25,000$17.02$425,500.00945,005View SEC Filing Icon  
9/1/2020Sell25,000$17.83$445,750.00977,618View SEC Filing Icon  
7/1/2020Sell25,000$18.91$472,750.001,027,268View SEC Filing Icon  
6/15/2020Sell25,000$21.65$541,250.00View SEC Filing Icon  
1/9/2020Sell18,641$17.95$334,605.951,012,783View SEC Filing Icon  
1/7/2020Sell16,090$18.20$292,838.001,012,783View SEC Filing Icon  
11/4/2019Sell50,765$12.67$643,192.55
See Full Table

Jin-Long Chen Buying and Selling Activity at NGM Biopharmaceuticals

This chart shows Jin-Long Chen's buying and selling at NGM Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NGM Biopharmaceuticals Company Overview

NGM Biopharmaceuticals logo
NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its lead product candidate, aldafermin, is designed for the treatment of patients with non-alcoholic steatohepatitis, with liver fibrosis stage 2, 3, or 4. The company was founded by Jin-Long Chen on December 20, 2007 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $22.26
Low: $21.61
High: $22.64

50 Day Range

MA: $22.19
Low: $20.15
High: $26.19

2 Week Range

Now: $22.26
Low: $14.90
High: $32.12

Volume

534,094 shs

Average Volume

365,168 shs

Market Capitalization

$1.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02
Billion-Dollar Crypto Fund Dumps Bitcoin for $2 "3rd-Gen" Crypto
The Wall Street Journal Calls It the "Latest Cryptocurrency to Surge."

Here's Why It Could Be Bigger Than Bitcoin.
Learn more.
pixel